Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

A randomized, double-blind, placebo-controlled phase I trial was conducted in 32 HIV-uninfected healthy volunteers to assess the safety and immunogenicity of 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC-M4) or 3 doses of TBC-M4 alone (groups A a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hayes, Peter, Gilmour, Jill, von Lieven, Andrea, Gill, Dilbinder, Clark, Lorna, Kopycinski, Jakub, Cheeseman, Hannah, Chung, Amy, Alter, Galit, Dally, Len, Zachariah, Devika, Lombardo, Angela, Ackland, James, Sayeed, Eddy, Jackson, Akil, Boffito, Marta, Gazzard, Brian, Fast, Patricia E., Cox, Josephine H., Laufer, Dagna
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2013
Teme:
Vaccines
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3592345/
https://ncbi.nlm.nih.gov/pubmed/23345581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00637-12
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items